Bruce L.A. Carter, Ph.D. has served on our Board of Directors since November 2013 and as our Chairman of the Board since December 2015. Dr. Carter is an Affiliate Professor in the Department of Biochemistry at the University of Washington, Seattle, Washington since 1986. He served as Executive Chairman of Immune Design Corp., a privately held biotechnology company, from November 2009 to November 2011 and he served as a director from 2000 to January 2009. From 1998 to 2009, Dr. Carter served as President and Chief Executive Officer of ZymoGenetics, Inc., a public biotechnology company, and as its Chairman of the Board from 2005 until it was acquired by Bristol-Myers Squibb in October 2010. From 1994 to 1998, Dr. Carter was the Chief Scientific Officer of Novo Nordisk, a public pharmaceutical company. Previously he held positions in research at ZymoGenetics and G.D. Searle & Co. Ltd. Dr. Carter serves as a director of Dr. Reddy’s Laboratories Limited, a public pharmaceutical company and Mirati Therapeutics, a public biopharmaceutical company. Dr. Carter holds a Ph.D. in microbiology from Queen Elizabeth College, University of London and a B.Sc. with Honors in botany from the University of Nottingham, England.
Mark G. Foletta was elected to our Board of Directors in June 2020. Mr. Foletta had been the Chief Financial Officer and Executive Vice President of Tocagen, Inc., a publicly-traded biotechnology company, from February 2017 until its merger with Forte Biosciences in June 2020. Mr. Foletta previously served as Senior Vice President, Finance and Chief Financial Officer of Amylin Pharmaceuticals, Inc., a publicly traded pharmaceutical company, from March 2006 through Amylin’s acquisition by Bristol Myers-Squibb Company in August 2012, and as Vice President, Finance and Chief Financial Officer of Amylin from 2000 to 2006. Previously, Mr. Foletta held a number of management positions with Intermark, Inc. and Triton Group Ltd. from 1986 to 2000 and served as an Audit Manager with Ernst & Young. From August 2015 to July 2016, Mr. Foletta served as the interim CFO of Biocept, Inc., a public diagnostics company. Mr. Foletta is an independent director of DexCom, Inc., a public medical device company where he also serves as Lead Director, and AMN Healthcare Services, Inc., a public healthcare services company. Mr. Foletta received a B.A. in Business Economics from the University of California, Santa Barbara.
Yujiro S. Hata was elected to our Board of Directors in August 2021. He has more than 20 years of experience building companies that have developed innovative therapies. Mr. Hata currently serves as the Founder and CEO of IDEAYA Biosciences, an oncology-focused precision medicine company, which he founded in 2015. From 2015 to 2018, Mr. Hata served as an Executive-in-Residence at 5AM Ventures. From 2014 to August 2015, he was Chief Operating Officer at Flexus Biosciences where he helped lead the company through its acquisition by Bristol-Myers Squibb in April 2015, and then he served as Chief Operating Officer at RAPT Therapeutics (formerly FLX Bio). Before then, Mr. Hata held roles of increasing responsibility, most recently as Vice President, Corporate Development and Strategy, at Onyx Pharmaceuticals. Previously Mr. Hata held business development roles at Enanta and at ImClone Systems, now a subsidiary of Eli Lilly and Company. Mr. Hata serves on the Boards of Directors of Xencor and Expansion Therapeutics and is a Board Member of the Moores Cancer Center at the University of California, San Diego. He obtained his M.B.A. from the University of Pennsylvania, his B.A. in Chemistry from Colorado College, and participated in undergraduate studies in Chemistry and Biology at Oxford University.
Kristine Peterson has served as a member of our Board of Directors since September 2017. Ms. Peterson has over 30 years of senior executive experience in commercial and business leadership roles in the pharmaceutical and biotechnology industry. From 2009 to 2016, Ms. Peterson served as Chief Executive Officer of Valeritas, Inc., a commercial-stage medical technology company where, under her leadership, the organization evolved from a research stage company to a commercial enterprise. Previously she held executive global marketing and commercial roles at Johnson & Johnson from 2004 to 2009, most recently as Company Group Chair, Biotech Sector, where she was responsible for commercial, R&D, and biologics manufacturing for biotech, oncology, immunology and cell therapy. From 2003 to 2004, she served as Senior Vice President, Commercial Operations for Biovail Corporation and President of Biovail Pharmaceuticals. Earlier in her career, she spent 20 years at Bristol-Myers Squibb Company in senior sales and marketing roles of increasing responsibility in a broad range of therapeutic areas that included Cardiovascular, Metabolic, Anti-infective, Virology, Neuroscience, Immunology/Inflammation, Pulmonary, and Oncology. Ms. Peterson currently serves on the Boards of Directors of Amarin Corporation plc, ImmunoGen, Inc. and Paratek Pharmaceuticals, Inc, all of which are public biopharmaceutical companies. She received a M.B.A and a B.S. from the University of Illinois at Urbana-Champaign.
Lesley Russell MBChB, MRCPb was elected to our Board of Directors in November 2016. Dr. Russell served as Chief Medical Officer of Innocoll Holdings Plc., a public biotechnology company, from April 2016 until November 2017, prior to which Dr. Russell served as Chief Operating Officer and Chief Medical Officer of TetraLogic Pharmaceuticals, another public biotechnology company, from August 2013. Dr. Russell was a medical executive with Cephalon, Inc. from January 2000 to 2011, most recently as Executive Vice President and Chief Medical Officer from September 2006 until October 2011, when Cephalon was acquired by Teva Pharmaceuticals. Dr. Russell served as a Senior Vice President and Global Head, Research and Development for Global Branded Products from the acquisition until July 2012. Dr. Russell previously held positions in medical research at US Bioscience, Eli Lilly and Amgen. Dr. Russell serves as an independent director of Imugene Limited, an Australian public biotechnology company, Chimeric Therapeutics Limited, an Australian public biotechnology company, and Scopus Biopharma, a public biotechnology company. Dr. Russell holds a Bachelor of Medicine, Bachelor of Surgery (MBChB) from the University of Edinburgh and is a member of the Royal College of Physicians (MRCP), UK.
Terry Vance has served as a member of our Board of Directors since June 2011. From June 2013 until November 2018, Mr. Vance was Chief Business Officer of BioMotiv, LLC, a drug development company affiliated with the Harrington Project. Until January 2018, Mr. Vance was a Managing Member of EGS Healthcare, a late-stage venture capital fund that he co-founded in 2002. Before starting EGS Healthcare, Mr. Vance was a founding partner in Eagle Advisors, which provided strategic advice to emerging biotechnology companies. Prior to Eagle, Mr. Vance was an investment banker, first with Salomon Brothers and then with Goldman Sachs, where he was a vice president in the Capital Markets Division. Mr. Vance received an AB from Princeton University and an M.B.A from Stanford University.
Dr. Jay Luly has been leading Enanta since July 2003, having successfully navigated and grown Enanta through its venture-financed years, its successful IPO in 2013, and three major collaborations delivering over $1 billion in non-dilutive financing to date. Under Dr. Luly’s leadership, Enanta collaborated with AbbVie in the discovery and development of two novel hepatitis C virus protease inhibitors: glecaprevir and paritaprevir, which are part of the combination regimens commercialized as MAVYRET® (U.S.)/MAVIRET® (ex-U.S.) and VIEKIRA PAK®, respectively. MAVYRET (glecaprevir/pibrentasvir) which was approved by the FDA in 2017, requires only eight weeks of treatment, the shortest duration of any hepatitis C regimen.
Prior to joining Enanta, Dr. Luly was an Entrepreneur in Residence at Oxford Bioscience Partners. Previously, Dr. Luly held the positions of Senior Vice President, Research and Development Operations and Senior Vice President, Discovery Strategy and Operations at Millennium Pharmaceuticals following Millennium’s acquisition of LeukoSite, Inc. in 1999. Dr. Luly had served as Senior Vice President, Drug Discovery and Preclinical Development at Leukosite, prior to which he held several senior drug discovery positions at Abbott Laboratories from 1983 to 1997.
Dr. Luly received a B.S. in Chemistry from the University of Illinois, Urbana/Champaign and a Ph.D. in Synthetic Organic Chemistry from the University of California, Berkeley.